Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

NCT03214250 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

129

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG: APX005M
DRUG: Nivolumab
DRUG: Nab-Paclitaxel
DRUG: Gemcitabine

Sponsor

Parker Institute for Cancer Immunotherapy

Collaborators

[object Object]
[object Object]
[object Object]